Search | Clinical Trials Finder

Conditions: Pregnancy, Obesity, Preeclampsia
Interventions: Ultrasound Scan, MRI Scan, Ferumoxytol; Procedure · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Heart Disease
Interventions: Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 30 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions: sildenafil, placebo; Drug · Other
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Cryoballoon Pulmonary Vein Isolation - PVI; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Plasma Volume, Exercise Capacity Test - Bicycle, Posture Study; Radiation · Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anesthesia
Interventions: Needle-Free Jet Injection of 1 % lidocaine, traditional needle infiltration of 1% lidocaine; Device · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 1 Day to 3 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Mild Hypertension
Interventions: Placebo, ISIS 757456; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 6
States / cities: Tustin, California • Port Orange, Florida • Indianapolis, Indiana + 3 more

Conditions: Hypertension
Interventions: Placebo, ALN-AGT01; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 54
States / cities: Birmingham, Alabama • Tempe, Arizona • Beverly Hills, California + 44 more

Conditions: Hypertension, Hemorrhage
Interventions: clevidipine; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more

Conditions: XXB750 in Healthy Participants
Interventions: XXB750, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pain
Interventions: clonidine, adenosine, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Winston-Salem, North Carolina

Conditions: Upper Gastrointestinal Hemorrhage
Interventions: Over-the-scope hemoclipping device, Standard endoscopic treatment; Device · Other
Lead sponsor: CURE Digestive Diseases Research Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Intracerebral Hemorrhage
Interventions: Intravenous nicardipine hydrochloride; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Blood Volume, Total Blood Volume, Exercise Capacity Test - Bicycle, Posture Study; Radiation · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: GERD
Interventions: Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy, Slow and rapid intra-esophageal infusion; Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pulmonary Arterial Hypertension
Interventions: PF-07868489, Placebo for PF-07868489; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Anaheim, California • Costa Mesa, California • Orange, California + 5 more

Conditions: Adenocarcinoma Pancreas
Interventions: PIPAC, Nab-paclitaxel; Device · Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Hypertension
Interventions: DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography; Drug · Procedure
Lead sponsor: Wanpen Vongpatanasin; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: End-Stage Renal Disease
Interventions: Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 20 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 18
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more

Conditions: Low Back Pain, Chronic Low-back Pain, Acute Low Back Pain
Interventions: Ultrsound Guided Hydrodissection of the Thoracolumbar Fascia, Osteopathic Manipulative Treatment (OMT); Procedure
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Alopecia Areata
Interventions: MedJet Device with intralesional triamcinolone; Combination Product
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4; Other · Drug
Lead sponsor: D. Walter Wray; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: High Cardiovascular Risk, Hypertension
Interventions: Zilebesiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 139
States / cities: Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more

Search by objective public record fields.

Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

Does Sildenafil Increase Exercise Performance in Air Pollution?

Reduction of Radiation Dose and Contrast Use During Cryoballoon Pulmonary Vein Isolation

Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome

Needle-Free Lidocaine Injection vs Traditional Local Anesthesia in Infant Lumbar Puncture

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants

Clonidine Versus Adenosine to Treat Neuropathic Pain

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Dietary Salt in Postural Tachycardia Syndrome

Mechanisms Preventing Pharyngeal Reflux

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

Neural Mechanism of Aldosterone-induced Insulin Resistance

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

Physical Exam, Static & Dynamic Ultrasound Assessment, & Treatment of Thoracolumbar Fascia (TLF) Mediated Low Back Pain

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

: Vascular Function in Health and Disease

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)